Tandem Diabetes t:slim X2 care study demonstrates improvement in all endpoints

The company states: "Tandem Diabetes announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology. Presented today at the 22nd Annual Diabetes Technology Meeting, the data demonstrated the system to be safe during 6 weeks of use, with a substantial improvement in time in range and mean glucose related to a reduction in hyperglycemia and no increase in continuous glucose monitor CGM-measured hypoglycemia. Both prior multiple daily injection users and prior basal insulin only users showed similar levels of improvement. Study participants indicated a high level of satisfaction with the system."